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Objectives. The contribution of nitric oxide (NO) and adenosine
to the increase in coronary blood flow (CBF) induced by cardiac
pacing was investigated in 28 subjects with angiographically
normal coronary arteries with and without one or more risk
factors for atherosclerosis.
Background. NO and adenosine are important in the regulation
of coronary circulation, and the inhibition of NO synthesis
increases adenosine production during cardiac pacing in experi-
mental models.
Methods. Coronary artery diameters and CBF were assessed by
quantitative coronary arteriography and Doppler flow velocity
measurement. Plasma levels of nitrites and nitrates (NOx) (stable
end products of NO), adenosine and lactate were measured, and
blood gas analysis was performed.
Results. The extent of CBF response to cardiac pacing did not
differ between the 14 subjects with and the 8 subjects without risk
factors for atherosclerosis. NOx (12.0 6 0.9 vs. 14.9 6 1.1
mmol/liter [mean 6 SD], p < 0.05), but not adenosine (50.8 6 7.2
vs. 50.8 6 6.5 nmol/liter), levels in coronary sinus blood increased
in the subjects without risk factors. In contrast, adenosine (58.9 6
7.5 vs. 77.4 6 9.8 nmol/liter, p < 0.05), but not NOx (11.1 6 1.1 vs.
12.2 6 1.1 mmol/liter), levels increased in subjects with risk
factors. Aminophylline, an antagonist of adenosine receptors,
blunted CBF response to cardiac pacing in six subjects with risk
factors. The number of risk factors showed a negative correlation
(p < 0.05) with NOx production and a positive correlation (p <
0.05) with adenosine production during cardiac pacing, respec-
tively.
Conclusions. NO and adenosine are increased during metabolic
coronary vasodilation induced by cardiac pacing. Adenosine pro-
duction may be a compensatory mechanism when NO production
is reduced.
(J Am Coll Cardiol 1998;31:1274–9)
©1998 by the American College of Cardiology
Coronary blood flow (CBF) increases in response to an
increased metabolic demand of the myocardium (1). Although
the precise mechanism remains unknown, it is likely that
metabolic, myogenic and endothelial factors are involved in
the regulation of the tone of coronary smooth muscle (2). The
vascular endothelium plays an important role in the modula-
tion of smooth muscle function by releasing vasoactive sub-
stances (3,4). Nitric oxide (NO) is an important endothelium-
derived relaxing factor (5,6), the release of which can be
stimulated by a variety of pharmacologic agents (7) and by
physiologic stimuli that increase shear stress in blood vessels
(8,9). Although several studies have shown that an inhibitor of
NO synthase reduces the CBF response to increased myocar-
dial oxygen consumption (MVO2) induced by rapid pacing in
dogs (10) and humans (11), others have detected no such
effects in these models (12,13). Also, it has not been clarified
whether NO levels indeed increase in response to increased
MVO2.
The development of risk factors for atherosclerosis, such as
hypercholesterolemia (HC), hypertension (HTN) or diabetes
mellitus (DM), may reduce the vasodilator response to phar-
macologic agents, indicative of endothelial dysfunction (11,14–
16). Recently, Quyyumi et al. (11) showed that both the extent
of the CBF response to cardiac pacing and the contribution of
NO to this response are reduced in subjects with risk factors
for coronary atherosclerosis. Adenosine is a potent vasodilator
that participates in the regulation of the coronary circulation
(1,17). The inhibition of NO synthesis increases adenosine
production under baseline conditions (18,19), during the in-
crease in CBF after brief periods of myocardial ischemia (20)
and during increased MVO2 induced by pacing (21), suggesting
that adenosine production increases when NO production is
impaired. However, it is not clear whether risk factors affect
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the production of NO or adenosine, or both, during stress and
whether adenosine compensates for the CBF response to
cardiac pacing when NO production is impaired in humans.
In the present study, we measured plasma levels of nitrites
and nitrates (NOx), stable end products of NO (22) and
adenosine in coronary sinus blood during cardiac pacing in
subjects with angiographically normal coronary arteries with
and without risk factors for atherosclerosis. We also examined
the role of increased adenosine during cardiac pacing in the
subjects with risk factors by means of aminophylline, an
antagonist of adenosine receptors (23). We further determined
whether the presence of risk factors affects production of NOx
and adenosine during cardiac pacing.
Methods
Subjects. We studied 28 subjects with angiographically
normal or nearly normal (,5% narrowing) coronary arteries
undergoing diagnostic cardiac catheterization for evaluation of
chest pain (Table 1). Subjects with previous myocardial infarc-
tion, valvular heart disease or evidence of left ventricular
dysfunction were excluded. Eight subjects (two men, six wom-
en; mean [6SD] age 61 6 2 years) had none of the following
risk factors for atherosclerosis: HTN (blood pressure
.140/90 mm Hg), HC (serum total cholesterol .220 mg/dl) or
DM (fasting blood glucose .110 mg/dl). The remaining 22
Abbreviations and Acronyms
ANOVA 5 analysis of variance
CBF 5 coronary blood flow
CVR 5 coronary vascular resistance
DM 5 diabetes mellitus
HC 5 hypercholesterolemia
HTN 5 hypertension
MVO2 5 myocardial oxygen consumption
NO 5 nitric oxide
NOx 5 nitrites and nitrates
Table 1. Patient Characteristics
Subject
No./Gender
Age
(yr)
Cholesterol Level
(mg/dl) HTN DM
Medical Therapy
Nitrates
Calcium Channel
Blocker Beta-Blocker ACEI
No risk factors
1/F 44 164 2 2 2 1 2 2
2/F 66 192 2 2 1 1 2 2
3/F 63 214 2 2 2 2 2 2
4/M 60 183 2 2 2 2 2 2
5/M 67 215 2 2 2 2 2 2
6/F 52 170 2 2 1 2 2 2
7/F 74 146 2 2 1 2 2 2
8/F 53 218 2 2 2 1 2 2
Risk factors
9/F 67 174 1 2 1 2 2 1
10/M 68 138 2 1 1 1 2 2
11/M 74 180 1 1 2 2 1 2
12/M 72 227 2 2 1 2 2 2
13/M 59 226 1 2 2 1 2 2
14/F 63 266 2 2 1 2 2 2
15/M 66 253 1 1 1 1 2 2
16/M 57 218 1 2 1 2 1 2
17/M 66 187 1 2 1 1 2 1
18/F 71 241 1 2 2 1 2 2
19/M 62 194 1 1 2 2 2 2
20/M 68 252 1 1 2 1 2 2
21/F 58 243 2 1 1 2 2 2
22/F 71 226 1 2 1 2 2 2
Risk factors 1
aminophylline
23/M 56 204 1 2 2 1 2 2
24/M 67 114 1 1 2 1 2 2
25/F 81 230 2 2 2 2 2 2
26/F 62 200 1 2 2 1 2 2
27/F 53 173 1 2 2 1 2 2
28/M 51 215 1 1 2 2 2 1
ACEI 5 angiotensin-converting enzyme inhibitor; DM 5 diabetes mellitus; F 5 female; HTN 5 hypertension; M 5
male; 1 5 yes; 2 5 no.
1275JACC Vol. 31, No. 6 MINAMINO ET AL
May 1998:1274–9 NO AND ADENOSINE IN METABOLIC CORONARY VASODILATION
subjects with one or more of these risk factors were classified
into two groups: 14 subjects without (9 men, 5 women; mean
age 66 6 1 years) and 6 subjects with (3 men, 3 women; mean
age 62 6 5 years) aminophylline treatment before pacing.
Protocol. Cardiac catheterization was performed with sub-
jects in the fasting state. Antianginal and antihypertensive
medications were discontinued at least 12 h before the study. A
6F bipolar pacing catheter was positioned at the right atrium.
After baseline hemodynamic variables at steady state were
recorded, the pacing rate was increased by 20 beats/min every
3 min to the highest rate attainable without inducing second-
degree atrioventricular block. CBF velocity was measured with
a Doppler flow wire, and coronary arteriography was per-
formed at rest and immediately after the end of the highest
pacing rate. Coronary sinus blood was sampled at each steady
state. In six subjects with risk factors, the effects of adenosine
antagonism with aminophylline on the CBF response to pacing
were assessed (23). After aminophylline was infused intrave-
nously at the dose of 6 mg/kg body weight over 10 min, the
previous protocol was repeated. The study protocol was ap-
proved by the institutional review committees on human
research of Osaka University School of Medicine and Ishinkai
Yao General Hospital. All subjects gave written informed
consent.
Estimation of coronary artery diameter and blood flow.
Coronary angiograms were recorded with a cineangiographic
system (Toshiba). Quantitative angiography was performed
with ARTEK software (CCIP-310, Cathex, Tokyo, Japan) (24).
An appropriate view that permitted clear visualization of the
target artery was selected. The view angle, the distance from
the X-ray focus to the object and the distance from the object
to the image intensifier were maintained constant during the
study. An end-diastolic frame of the arteriogram was selected,
and the lumen diameter of the segment of the artery distal to
the Doppler wire was determined with a validated densitomet-
ric analysis system. The diameters were measured by examiners
who had no knowledge of the clinical characteristics of the
subjects. The size of the Judkins catheter was used to calibrate
the arterial diameter. A 6F guide catheter was introduced into
the left main coronary artery, and blood flow velocity was
measured with an 0.018-in. wire equipped with a Doppler
crystal at its tip (Cardiometrics FloWire) (16). The Doppler
flow wire was advanced into either the left main coronary
artery or the proximal segment of a major epicardial coronary
artery. CBF was calculated from p 3 Average peak flow
velocity 3 0.125 3 (Arterial diameter)2 (16). Coronary vascu-
lar resistance (CVR) was calculated as the mean arterial
pressure divided by CBF. A 7F multipurpose catheter was
inserted through the right cubitus vein into the mid-coronary
sinus for blood sampling.
Chemical analysis. Plasma levels of lactate in coronary
sinus venous blood were determined enzymatically (25). The
lactate extraction ratio was calculated by the following for-
mula: (Arterial lactate level 2 Venous lactate level)/Arterial
lactate level 3 100 (26). Blood gas analysis was performed with
an ABL300 blood gas analyzer (Radiometer, Copenhagen,
Denmark). MVO2 was calculated as the product of CBF and
the difference in oxygen content of coronary artery and venous
blood. Plasma levels of adenosine were measured by radioim-
munoassay, as previously described (26,27). Adenosine is
thought to be degraded rapidly (1,17). To minimize this
degradation, we sampled blood with a syringe containing
dipyridamole, an inhibitor of adenosine uptake, and added the
samples to the solution that contained an inhibitor of adeno-
sine deaminase and a chelator of calcium. The sampling time
was ,10 s for all subjects. Although some amount of adenosine
may have been degraded during the sampling period, the
sampling times at rest and at the end of cardiac pacing were
similar. Thus, the ratio of the measured to absolute levels of
adenosine should have been similar at rest and at the end of
cardiac pacing. Plasma NOx levels were assayed with the
Griess reagent, as previously described (28).
Statistical analysis. Results are expressed as mean value 6
SD. Serial changes in plasma NOx and adenosine levels and
hemodynamic variables during cardiac pacing in subjects with
and without risk factors were compared using two-way re-
peated measures analysis of variance (ANOVA). Hemody-
namic and angiographic variables under baseline conditions
among the subjects with and without risk factors and those
treated with aminophylline were compared with one-factorial
ANOVA followed by the Bonferroni multiple comparison test.
The total number of risk factors was considered a continuous
variable and examined by linear regression analysis. Finally,
the effects of risk factors on NOx and adenosine production
were examined by multiple linear regression analysis. A p value
,0.05 was considered statistically significant.
Results
There were no significant differences in hemodynamic
variables, such as heart rate, rate-pressure product, MVO2,
lactate extraction ratio, coronary artery diameter, CBF and
CVR during baseline conditions between subjects with and
without risk factors (Table 2). Cardiac pacing significantly (p ,
0.05) increased rate-pressure product, MVO2, coronary artery
diameter and CBF and decreased CVR in subjects with and
without risk factors, respectively (Table 2). NOx and adenosine
levels in coronary sinus blood during baseline conditions did
not differ significantly between subjects with and without risk
factors (Fig. 1). In subjects without risk factors, NOx, but not
adenosine, levels increased in response to cardiac pacing (Fig.
1). In contrast, in subjects with risk factors, adenosine, but not
NOx, levels increased in response to cardiac pacing (Fig. 1).
Intravenous infusion of aminophylline did not significantly
change heart rate (70 6 4 vs. 78 6 4 beats/min), mean blood
pressure (109 6 6 vs. 114 6 6 mm Hg) or rate-pressure product
(76 6 7 vs. 89 6 7 mm Hgzbeats/minz1022). Hemodynamic
variables in subjects treated with aminophylline did not signif-
icantly differ from those at baseline in subjects with and
without risk factors. Aminophylline blunted the increases in
CBF and coronary artery diameter in response to cardiac
pacing in subjects with risk factors (Table 2).
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The presence of HC, HTN or DM did not affect baseline
NOx or adenosine levels. Multiple linear regression analysis
revealed that NOx production negatively correlated with the
presence of DM (p , 0.05) and adenosine production posi-
tively correlated with the presence of HTN (p , 0.05). The
correlation between NOx production and risk factors other
than DM and between adenosine production and risk factors
other than HTN was not significant. The number of risk factors
showed a negative correlation with NOx production (Fig. 2A)
and a positive correlation with adenosine production (Fig. 2B)
during cardiac pacing.
Discussion
Contribution of NO and adenosine to metabolic coronary
vasodilation in subjects without risk factors. CBF increases in
response to increased metabolic demands of the myocardium
(1). The contribution of NO to the CBF response to increased
MVO2 remains controversial (10–13). In previous experimen-
tal and clinical studies (10–13), the role of NO in the CBF
response to increased MVO2 was evaluated with the use of an
inhibitor of NO synthase. NO rapidly decomposes to form
NOx in the body (22), and endogenous production of NO can
be detected by assaying the plasma NOx levels (29). We
showed that plasma NOx levels in coronary sinus blood were
increased in response to the increase in MVO2 induced by
cardiac pacing in subjects with angiographically normal coro-
nary arteries without risk factors for atherosclerosis. This
observation suggests that increased NO release may contribute
to the CBF response to increased MVO2 in subjects without
risk factors.
In contrast, the contribution of adenosine to the CBF
response to increased MVO2 is not well understood. Several
studies (30,31) have suggested that adenosine plays an impor-
tant role in CBF response to increased MVO2, however,
Rossen et al. (23) detected no change in CBF response to
increased MVO2 after antagonism of adenosine receptors. We
showed that adenosine levels in coronary sinus blood did not
change during coronary vasodilation in subjects with angio-
graphically normal coronary arteries without risk factors, sug-
gesting that adenosine may not contribute to the CBF response
to increased MVO2 in these subjects.
Influence of risk factors. We demonstrated that plasma
NOx levels in coronary sinus blood did not increase during
cardiac pacing in subjects with angiographically normal coro-
nary arteries with risk factors, consistent with the results of
Quyyumi et al. (11) that the contribution of NO to CBF
response to cardiac pacing is reduced in these subjects. The
Figure 1. Response of NOx and adenosine levels in coro-
nary sinus blood to cardiac pacing in subjects with (solid
circles) and without risk factors (open circles). Data shown
mean value 6 SD. *p , 0.05 versus subjects without risk
factors.
Table 2. Changes in Hemodynamic and Metabolic Variables During Cardiac Pacing
No Risk Factors Risk Factors
Risk Factors 1
Aminophylline
Baseline Pacing Baseline Pacing Baseline Pacing
HR (beats/min) 70 6 10 128 6 5* 70 6 10 131 6 9* 78 6 9 138 6 21*
RPP (mm Hgzbeats/minz1022) 94 6 11 173 6 16* 98 6 21 181 6 26* 89 6 18 163 6 21*
MVO2 (ml/min) 5.6 6 2.9 8.1 6 3.6* 4.5 6 4.1 9.1 6 4.5* — —
Lactate extraction ratio (%) 30 6 23 36 6 25 35 6 11 32 6 10 — —
Coronary artery diameter (mm) 2.3 6 0.7 2.5 6 0.7* 2.1 6 0.4 2.3 6 0.5* 2.7 6 0.3 2.7 6 0.2
CBF (ml/min) 62 6 30 98 6 40* 54 6 35 82 6 43* 48 6 18 57 6 17
CVR (mm Hgzml21 min) 3.3 6 2.0 1.8 6 1.2* 3.5 6 2.0 2.2 6 1.7* 2.6 6 0.8 2.2 6 0.5
*p , 0.05 versus baseline value. Data presented are mean value 6 SD. CBF 5 coronary blood flow; CVR 5 coronary
vascular resistance; HR 5 heart rate; MVO2 5 myocardial oxygen uptake; RPP 5 rate-pressure product.
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present study demonstrated that the CBF response to cardiac
pacing was not impaired in subjects with risk factors. Because
NOx release was depressed in these subjects, another vasodi-
latory substance may increase to compensate for the reduced
coronary vasodilation caused by NO. Indeed, adenosine levels
in coronary sinus blood increased in response to the increase in
MVO2 in subjects with angiographically normal coronary ar-
teries with risk factors. Adenosine, which is a potent coronary
vasodilator (1,17), may compensate for the reduced function of
NO to maintain the CBF response to increased MVO2 in these
subjects. Indeed, we demonstrated that increases in CBF in
response to cardiac pacing were blunted by aminophylline, an
antagonist of adenosine receptors. These findings strongly
suggest that adenosine may compensate for the reduced func-
tion of NO to maintain the CBF response to increased MVO2
in subjects with risk factors for coronary atherosclerosis.
Several investigators (11,32) reported that subjects with risk
factors for atherosclerosis showed a depressed vasodilator
response to the increase in MVO2. However, we demonstrated
that the CBF response to cardiac pacing at nearly identical
cardiac metabolic status, as evidenced by MVO2 and lactate
extraction ratio, was similar between subjects with and without
risk factors. The discrepancy between our and other studies
might be attributable to the differences of the definition of risk
factors and the extent of stress. Risk factors in our subjects
were lower and the level of stress milder than that in previous
studies (11,32). It is possible that increased adenosine cannot
compensate totally for reduced NO production in the presence
of higher risk factors and greater stress.
We found no differences in plasma NOx levels during
baseline conditions between subjects with and without risk
factors. If risk factors are associated with a decrease in NO
production in response to cardiac pacing, why is NOx produc-
tion not decreased at rest? One possible explanation is that
only the capacity to produce NO in response to stress was
depressed in subjects with risk factors. Some coronary risk
factors may produce superoxide, which can chemically neutral-
ize NO by forming peroxynitrate (33). Because our assay for
NOx may also detect peroxynitrate, we may have overesti-
mated NO production under baseline conditions in subjects
with risk factors by using NOx levels as an indicator of NO
levels.
Interaction between NO and adenosine. Myocardial isch-
emia increases adenosine production (17,26), suggesting that
cardiac pacing may have induced myocardial ischemia in
subjects with risk factors in the present study. However, the
lactate extraction ratio, an index of myocardial ischemia, did
not differ at rest and at the end of cardiac pacing in these
subjects, suggesting that myocardial ischemia is not responsible
for the pacing-induced adenosine production observed in
subjects with risk factors.
Inhibition of NO synthesis increases adenosine production
under baseline conditions (18,19), during the increase in CBF
after brief periods of myocardial ischemia (20) and during
increased MVO2 induced by pacing (21). We recently showed
(19) that the inhibition of NO synthesis induced an increase in
ecto-59-nucleotidase activity and a consequent increase in
adenosine levels in open chest dog hearts. These observations
suggest that activation of ecto-59-nucleotidase might be one
possible mechanism for increased adenosine levels when NO
bioavailability is reduced. It is possible that the risk factors
themselves directly increase adenosine production under
pathophysiologic conditions.
The contribution of NO during coronary vasodilation in-
duced by cardiac pacing in clinical studies using an NO
synthase inhibitor remains undetermined (11,13). Because
inhibition of NO during cardiac pacing may affect production
of adenosine, which modifies coronary circulation (18–21), we
must interpret the results of those study using an NO synthase
inhibitor with care, and direct measurements of NOx and
adenosine in coronary venous blood may be useful for evalu-
ating the contribution of NO and adenosine to the coronary
circulation in humans.
Recently, Egashira et al. (32) and Zeiher et al. (34)
reported that endothelial dysfunction in highly selected pa-
tients with angiographically normal coronary arteries is asso-
ciated with noninvasive evidence for myocardial ischemia
during exercise stress. However, the present study suggests that
adenosine may compensate for the reduced NO production
that is indicative of endothelial dysfunction. One possible
Figure 2. Scatterplots of the relation between number of
risk factors of subjects and NOx (A) and adenosine (B)
production in coronary sinus blood in response to cardiac
pacing.
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explanation for this discrepancy is that adenosine as well as NO
production may be impaired in the highly selected subjects in
the studies of Egashira et al. (32) and Zeiher et al. (34).
Another possibility is that we assessed the CBF response to
relatively modest stress in our subjects compared with the
subjects of Egashira et al. (32) and Zeiher et al. (34). Thus, it
is possible that increased adenosine cannot compensate for
reduced NO production when the degree of stress is greater.
Clinical implications. Our findings suggest that reduced
NO production during stress may be compensated for by an
increase in adenosine production. Substitution of adenosine
may provide a strategy for preventing myocardial ischemia
during stress in patients with endothelial dysfunction.
We thank Kayoko Yoshida and Yukiyo Nomura for technical assistance.
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